Ligand Pharmaceuticals

Yahoo Finance • 15 days ago

CLO Sells LGND 5,000 Shares for $1.0 Million

Key Points 5,000 shares were sold on March 4, 2026, through an option exercise and immediate disposition, yielding a transaction value of ~$1.03 million at around $206.35 per share. The sale represented 11.94% of Reardon's direct holdings... Full story

Yahoo Finance • 19 days ago

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

JUPITER, Fla., March 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments an... Full story

Yahoo Finance • 25 days ago

Two Biotech Stocks Hover Near Highs; Natural Gas And Finance Names Show Resilience

Two biotech stocks, Ligand Pharmaceuticals and United Therapeutics, are showing resilient action in Friday's stock market. Continue Reading... Full story

Yahoo Finance • last month

Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Why Ligand Pharmaceuticals is in Focus Right Now Ligand Pharmaceuticals (LGND) is back on investor radars after Bank... Full story

Yahoo Finance • last month

Oracle, Nike upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: JPMorgan upgraded Oracle (ORCL) to Over... Full story

Yahoo Finance • last month

Ligand gains new Buy from BofA on high-margin, less risky narrative

[Wall Street New York stock exchange stock market] alexsl Ligand Pharmaceuticals (LGND [https://seekingalpha.com/symbol/LGND]) traded higher in the premarket on Wednesday after Bank of America launched its coverage with a Buy recommendati... Full story

Yahoo Finance • last month

Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More

Quick Read After a strong Monday, the stock market took a breather yesterday as investors continued to reset in anticipation of a changing investment landscape. The potential for a quick conclusion to the Iran war is keeping the selling p... Full story

Yahoo Finance • 2 months ago

Ligand Pharma (LGND) Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, February 26, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Todd DavisChief Financial Officer — Octavio EspinozaVice President, Portfolio Strategy and Investments — Lauren... Full story

Yahoo Finance • 2 months ago

Ligand: Q4 Earnings Snapshot

JUPITER, Fla. (AP) — JUPITER, Fla. (AP) — Ligand Pharmaceuticals Inc. (LGND) on Thursday reported fourth-quarter earnings of $44.8 million. On a per-share basis, the Jupiter, Florida-based company said it had net income of $2.12. Earnings... Full story

Yahoo Finance • 2 months ago

This $38.8 Million Vicor Bet Is Getting Bigger Amid a 200% Stock Surge

On February 13, 2026, Ashford Capital Management disclosed a buy of 128,664 shares of Vicor(NASDAQ:VICR), with an estimated transaction value of $10.94 million based on quarterly average pricing. What happened According to a filing with... Full story

Yahoo Finance • 2 months ago

What Investors Should Know as One Fund Sells $11 Million of Cavco Industries Stock

On February 13, 2026, Ashford Capital Management disclosed in a Securities and Exchange Commission filing that it reduced its position in Cavco Industries(NASDAQ:CVCO) by 19,607 shares, an estimated $11.11 million trade based on quarterly... Full story

Yahoo Finance • 2 months ago

Fund Sells $23 Million in Globalstar as Stock Surges 170% in One Year

On February 13, 2026, Ashford Capital Management reported selling 410,326 shares of Globalstar(NASDAQ:GSAT), with the estimated transaction value at $22.66 million based on quarterly average pricing. What happened According to an SEC fil... Full story

Yahoo Finance • 2 months ago

Chime Is Down 27% From Its IPO Price, Yet Posting 29% Revenue Growth: Why This New $15 Million Bet Stands Out

On February 13, 2026, Ranger Investment Management disclosed a new position in Chime Financial(NASDAQ:CHYM), acquiring 591,255 shares in a trade estimated at $14.88 million. What happened According to the SEC filing dated February 13, 20... Full story

Yahoo Finance • 2 months ago

Solaris Stock Is Up 100% This Past Year, and One Fund Is Betting $29 Million on More Growth

On February 13, 2026, Ranger Investment Management, L.P. disclosed a buy of 197,073 shares of Solaris Energy Infrastructure(NYSE:SEI), an estimated $9.53 million trade based on quarterly average pricing. What happened According to a fili... Full story

Yahoo Finance • 2 months ago

Stock Up 40% in a Year, $706 Million in Quarterly Sales: Why Boot Barn’s Trimmed Stake Deserves a Look

Ranger Investment Management disclosed on February 13, 2026, that it sold 99,800 shares of Boot Barn Holdings(NYSE:BOOT), an estimated $18.62 million transaction based on quarterly average pricing. What happened According to a recent SEC... Full story

Yahoo Finance • 4 months ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Introduces 2026 full year revenue guidance of $245 million to $285 million, an approximately 15% increase in core revenue growth over 2025, royalty revenue of $200 to $225 million, a 40% increase over 20251, and core adjusted earnings per... Full story

Yahoo Finance • 5 months ago

What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?

Summers Value Partners, an investment management company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The Summers Value Fund LP returned a net return of 20.4% net in Q3 2025, surpassing the... Full story

Yahoo Finance • 5 months ago

Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30... Full story

Yahoo Finance • 5 months ago

Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer

Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in the US from Biofrontera and Ferrer Internacional. The topical cream is indicated to treat impetigo, a bacterial... Full story

Yahoo Finance • 5 months ago

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in antibiotic-resistant skin infections cause... Full story